Elotuzumab
LCI-HEM-MYE-CRD-002
Phase 2 small_molecule completed
Quick answer
Elotuzumab for Multiple Myeloma is a Phase 2 program (small_molecule) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Atrium Therapeutics
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed